Prestige Consumer Healthcare (NYSE:PBH) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• Prestige Consumer Healthcare reported quarterly EPS of $1.13, beating estimates by $0.06, and revenue of $336.3 million, above expectations and up 22.7% year over year. Excluding acquisitions and currency effects, revenue declined 1.6%.
• Clear Eyes supply disruptions led the company to lower its fiscal 2027 outlook to revenue of $1.28 billion–$1.29 billion and adjusted EPS of $4.48–$4.55; management expects Clear Eyes sales below $20 million this year.
• Management said key brands and recent acquisitions are progressing well, with Breathe Right and LaCorium expected to contribute about $190 million in fiscal 2027 revenue. It also expects at least $265 million in adjusted free cash flow and plans to use cash to reduce debt.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) posted its earnings results on Thursday. The company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.06, FiscalAI reports. The business had revenue of $336.31 million for the quarter, compared to analyst estimates of $329.14 million. Prestige Consumer Healthcare had a net margin of 13.29% and a return on equity of 11.28%. Prestige Consumer Healthcare's revenue was up 22.7% compared to the same quarter last year. During the same period last year, the business posted $1.07 EPS.

Here are the key takeaways from Prestige Consumer Healthcare's conference call:

• Second-quarter revenue rose 22.7% to $336.3 million, reflecting the first full quarter of Breathe Right and LaCorium ownership; adjusted EPS increased about 6% to $1.13. Excluding acquisitions and foreign currency, revenue declined 1.6%, which management attributed partly to prior-quarter order timing.
• Clear Eyes production volatility prompted a cut to the full-year outlook. Prestige now expects fiscal 2027 revenue of $1.28 billion–$1.29 billion and adjusted EPS of $4.48–$4.55; it expects less than $20 million in Clear Eyes sales for the year and said supply recovery will take time.
• The company said its broader portfolio and recent acquisitions are performing well. First-half organic revenue grew about 1%, led by brands including Dramamine, TheraTears, Compound W, and Hydralyte; Breathe Right and LaCorium remain on track to contribute about $190 million in fiscal 2027 revenue.
• Prestige reported mid-teens e-commerce consumption growth and market-share gains for many leading brands, as shoppers seek value through online and mass-market channels. Management plans to use free cash flow to reduce debt, while forecasting at least $265 million in adjusted free cash flow for the year.

Prestige Consumer Healthcare Stock Performance

Shares of PBH traded down $1.29 during mid-day trading on Friday, hitting $43.03. The company's stock had a trading volume of 1,127,190 shares, compared to its average volume of 598,881. Prestige Consumer Healthcare has a one year low of $41.77 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.99 and a current ratio of 2.92. The firm has a market capitalization of $2.04 billion, a PE ratio of 13.28, a price-to-earnings-growth ratio of 1.35 and a beta of 0.30. The stock's 50-day moving average is $48.17 and its two-hundred day moving average is $53.77.

More Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings were $1.13 per share, topping the $1.07 consensus, while revenue of $336.31 million exceeded estimates of about $329 million and rose 22.7% year over year. Prestige Consumer Healthcare fiscal 2027 second-quarter results
• Neutral Sentiment: Canaccord Genuity lowered its price target from $72 to $70 but maintained a Buy rating. The reduced target is a mild negative, though it still implies substantial upside from the cited share price. Canaccord Genuity Group stock recommendations
• Negative Sentiment: A recent report highlights PBH’s stock drop, but the provided article details do not specify what is driving the decline. The weakness despite an earnings and revenue beat may indicate investors are weighing concerns not explained in the available coverage. Prestige Consumer Healthcare stock dropped: what is driving attention now?

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PBH shares. Zacks Research cut shares of Prestige Consumer Healthcare from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 29th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $67.00.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.